BeyondSpring (BeyondSpring) Float Percentage Of Total Shares Outstanding : 60.93% (As of May. 01, 2024)

View and export this data going back to 2017. Start your Free Trial

What is BeyondSpring Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeyondSpring's float shares is 23.77 Mil. BeyondSpring's total shares outstanding is 39.02 Mil. BeyondSpring's float percentage of total shares outstanding is 60.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeyondSpring's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeyondSpring's Institutional Ownership is 0.29%.

BeyondSpring Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BeyondSpring's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	23.77	/	39.02
	=	60.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeyondSpring (BeyondSpring) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeyondSpring Inc (NAS:BYSI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Liberty Street, 39th Floor, New York, NY, USA, 10005

Website

https://www.beyondspringpharma.com

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform. It has a scalable business model integrating clinical resources in the United States and China.